Harvard Management Company’s Disc Medicine IRON Stock Holding History

Harvard Management Company’s Portfolio IRON Stock Details IRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,452	Closed	-$375K	–	26
2023 Q2	$375K	Sell	8,452 -16,548	-66%	-$587K	0.04%	32
2023 Q1	$530K	Hold	25,000	–	–	0.06%	44
2022 Q4	$497K	Buy	25,000 +16,667	+200%	+$830K	0.06%	44
2022 Q3	$410K	Hold	8,333	–	–	0.05%	47
2022 Q2	$423K	Hold	8,333	–	–	0.05%	44
2022 Q1	$348K	Hold	8,333	–	–	0.04%	44
2021 Q4	$728K	Hold	8,333	–	–	0.07%	44
2021 Q3	$1.01M	Hold	8,333	–	–	0.06%	37
2021 Q2	$1.62M	Hold	8,333	–	–	0.09%	36
2021 Q1	$3.39M	Buy	+8,333	New	+$3.72M	0.19%	35

Other funds holding IRON

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Harvard Management Company's IRON Position: Q3 2023 in Review

Harvard Management Company sold out of Disc Medicine (IRON) in Q3 2023, closing a stake of 8,452 shares — an estimated $375K sold.

Harvard Management Company first reported a position in IRON in Q1 2021 and held it in 10 quarters. The position peaked at $3.39M in Q1 2021. 91 funds tracked by Wall St. Rank hold IRON as of Q3 2023.

Harvard Management Company reported no remaining Disc Medicine position as of Q3 2023 after selling out during the quarter.
Harvard Management Company sold 8,452 Disc Medicine shares in Q3 2023, an estimated $375K.
Harvard Management Company first reported a position in Disc Medicine in Q1 2021 and held it in 10 quarters.
Harvard Management Company's Disc Medicine position peaked at $3.39M in Q1 2021.
91 funds tracked by Wall St. Rank held Disc Medicine as of Q3 2023.

Based on Harvard Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.